Tarsons Products Peer Comparison

NSE: TARSONS | BSE: 543399

₹331.65

₹-0.60 (-0.18%)

As on 31-Aug-2026IST

Market cap

₹1,761 Cr

Revenue (TTM)

₹441 Cr

P/E Ratio

158.8

P/B Ratio

2.8

Div. Yield

0 %

Edit

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Market cap (₹ Cr)	1,761	21	47,647	17,871	8,072
Revenue (₹ Cr)	441	0	6,725	1,997	7,229
Net Profit (₹ Cr)	11.10	-1.61	1,128.79	307.01	210.43
Net Margin (%)	2.37	-431.37	16.02	14.56	2.88
RoE (%)	1.88	-16.73	11.51	10.63	11.02
Price to Earnings	158.76	--	42.21	56.72	38.35
Price-To-Book	2.78	2.68	4.48	5.62	4.04

Income Statement (₹ Cr)

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Operating Revenue	441.39	0.22	6,725.30	1,997.43	7,229.43
Total Income	468.21	0.37	7,045.33	2,108.80	7,305.56
Total Expenditure	322.18	0.69	4,974.15	1,536.06	6,619.55
EBITDA	119.21	-0.46	1,751.15	461.36	609.88
Depreciation	103.61	0.19	433.87	128.17	295.17
EBIT	15.59	-0.65	1,317.28	333.19	314.71
Interest	23.74	1.11	26.14	21.84	126.40
Other Income	26.82	0.15	320.03	111.37	76.13
Exceptional Items	-1.13	0.00	-24.35	-6.80	0.00
Profit before Tax	17.54	-1.61	1,586.82	415.92	264.44
Provision for Tax	6.45	0.00	458.02	108.91	54.01
Profit after Tax	11.10	-1.61	1,128.79	307.01	210.43

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Shareholder's Funds	634.69	9.21	10,357.95	3,106.17	1,975.36
Minority Interest	0.00	0.00	0.00	2.16	0.04
Non-Current Liabilities	286.94	121.66	544.50	193.80	1,268.58
Current Liabilities	264.19	12.88	1,608.40	575.52	689.29
Total Liabilities	--	144.09	11,172.85	3,279.77	3,456.02

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Non-Current Assets	875.11	142.73	4,858.96	1,874.17	520.92
Current Assets	265.75	1.02	7,526.79	1,941.73	2,068.65
Total Assets	--	144.09	11,172.85	3,279.77	3,456.02
Total Debt*	--	14.52	269.21	177.65	0.00
Net Current Assets	1.56	-11.86	5,918.38	1,366.21	1,379.36
Contingent Liabilities	--	2.58	21.38	77.12	13.78

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Cash From Operating Activities	--	1.20	914.73	233.05	540.43
Cash Flow from Investing Activities	--	-1.70	1,704.74	-1,187.18	-317.61
Cash from Financing Activities	--	0.78	-433.48	950.51	-227.98
Net Cash Inflow / Outflow	--	0.28	2,185.99	-3.63	-5.16

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
ROCE (%)	--	-1.75	11.97	20.37	18.22
ROE (%)	1.88	-16.73	11.51	10.63	11.02
ROA (%)	0.98	-1.13	9.51	8.63	5.77
EBIT Margin (%)	3.53	-293.27	19.59	16.68	4.35
Net Margin (%)	2.37	-431.37	16.02	14.56	2.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Revenue Growth (%)	10.63	-14.89	17.57	18.31	16.79
EBIT Growth (%)	-65.55	32.58	33.69	-9.66	17.15
Net Profit Growth (%)	-59.71	-22.92	46.55	-12.67	18.07
EPS Growth (%)	-57.00	-22.92	48.78	-10.52	17.73
Book Value Growth (%)	--	-6.38	4.91	88.41	10.77

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Price / Earnings	148.35	-13.52	41.44	55.73	38.32
Price / Book Value	2.77	2.72	4.47	5.61	4.04
Dividend Yield (%)	0.00	0.00	0.69	0.20	0.00
EV/EBITDA	17.27	-77.71	25.37	37.62	12.49
Market Cap (₹ Cr)	--	25.38	26,233.01	22,718.23	9,091.18

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Debt to Equity	0.33	0.70	0.01	0.02	0.00
Short term debt to equity ratio	--	0.84	--	0.06	--
Current Ratio	1.01	0.08	4.68	3.37	3.00
Quick Ratio	0.51	0.08	3.60	2.62	1.00
Interest Coverage	1.74	-0.46	61.70	20.04	3.09

	Tarsons Products	Transgene Biotek	Gland Pharma	Poly Medicure	Medplus Health
Debtors to sales (%)	19.35	3.59	28.12	26.59	0.37
Asset Turnover	0.39	0.00	0.57	0.56	1.98
Receivable days	--	11.76	99.92	67.43	0.90
Inventory Days	--	47.53	108.54	55.13	78.76
Payable days	--	--	138.65	74.14	21.71
Cash Conversion Cycle	--	--	69.81	48.42	57.95

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.